
---
title: '猴腺病毒载体狂犬病候选疫苗'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=5144'
author: 科学网
comments: false
date: Sun, 07 Aug 2022 07:11:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=5144'
---

<div>   
<p style="line-height: 200%"><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">猴腺病毒载体狂犬病候选疫苗——</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">低成本</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">、</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">单剂</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">量、适用于</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px">暴露前预防</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 35px"> </span></strong></p><p style="margin-left: 0;text-indent: 63px;line-height: 200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">英国牛津大学和美国费城威斯塔（</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF">Wistar</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">）研究所的研究人员合作于</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">7月</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">27</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">日</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">在国际顶级医学期刊《</span></span></strong><strong><em><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">Lancet Microbe</span></span></em></strong><strong><em><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"> <span style="font-family:Microsoft YaHei UI">》</span></span></em></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">上发表研究论文：《</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">猴腺病毒载体狂犬病疫苗的安全性和免疫原性</span>:一项</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">非盲、</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">非随机</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">、</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">剂量递增</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">、</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">单中心</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">、</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">首次</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">用于</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">人</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">类的</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">一期临床试验</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">（</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"> </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">Safety and immunogenicity of a simian-adenovirus</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF">vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">）》</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">（见参考文献）</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">。</span></span></strong></p><p style="margin-left: 0;text-indent: 63px;line-height: 200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF">ChAdOx2 RabG是一种</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">用</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">猴腺病毒</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">作</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">载体的狂犬病候选疫苗，可能有潜力提供</span><a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a><span style="font-family:Microsoft YaHei UI">低成本</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">、</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">单剂量</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">的</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">暴露前狂犬病预防</span><span style="font-family:Microsoft YaHei UI">。这项首次人体研究旨在评估其在健康成人中的安全性和免疫原性。</span></span></strong></p><p style="margin-left: 0;text-indent: 63px;line-height: 200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">现简介此项研究的主要内容。</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF"> </span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">研究背景</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:ScalaLancetPro-Bold">狂犬病每年导致大约</span>6万人死亡。</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 24px">研究前的证据</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">为了确定其他新的狂犬病候选疫苗，搜索</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">了</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">PubMed</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">，用了</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">以下搜索词</span>:(病毒载体)或(1期)</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">和</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">(狂犬病疫苗)</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">和</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">(临床试验)。没有使用时间或语言限制。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">发现有</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">5项研究涵盖了3种候选疫苗:两种</span><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">狂犬病糖蛋白</span>(RabG</span></span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">)编码mRNA</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">候选</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">疫苗</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">进行了</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">1期临床试验</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">，</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">分别使用基于</span><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">鱼精蛋白</span></span></span><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">（</span></span></span><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"> protamine</span></span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">）</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">的配方</span>(CV7201)和脂质纳米颗粒配方(CV7202)。此外，还</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">发现</span><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">金丝雀痘</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">病毒</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">载体疫苗</span>(ALVAC-RG)</span></span></strong><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">的三</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">项</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">试验。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">根据剂量和给药途径的不同，</span><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">CV7201</span></strong><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">在高达</span>83%的志愿者中诱导的病毒中和抗体</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">超过</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">0.5 IU/mL阈值(表示疫苗接种</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">成功</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">)，但需要使用专门的给药装置多次给药以</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">达到</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">这一阈值。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">CV7202</span></strong><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">作为两剂方案具有适度的免疫原性，但单剂</span>(任何剂量水平)诱导</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">的</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">病毒中和抗体滴度</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">未能达到能证明有适当反应的</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">阈值。</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">而</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">高剂量不能很好地耐受，</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">因此</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">需要暂时停止</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">此项</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">研究。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">当以</span>4周为间隔</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">期</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">两次注射时，</span>ALVAC-RG被证明具有良好的耐受性和免疫原性，但在</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">第一次加强注射后没有引起强烈的反应，而且似乎比已经批准的狂犬病疫苗的免疫原性更低。</span></p><p style="line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><strong style="white-space: normal;"><span style="font-family: Shaker2Lancet-Bold; line-height: 58px; color: #B30437; font-size: 29px;">方法</span></strong></span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">在英国牛津大学的临床疫苗学和热带医学中心对ChAdOx2 RabG进行了一项单中心一期临床研究，采用单次肌肉注射剂量，非随机、非盲、剂量递增的方式。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">健康成人被依次分配到接受低剂量(5×10⁹ 病毒颗粒)、中剂量(2·5×</span><strong><span style="font-family: ScalaLancetPro-Bold;color: #231F20;font-size: 21px">101⁰</span></strong><span style="font-family: Shaker2Lancet-Regular; line-height: 200%; color: #231F20; font-size: 21px;">病毒颗粒)和高剂量(5x</span><strong><span style="font-family: ScalaLancetPro-Bold;color: #231F20;font-size: 21px">101⁰</span></strong><span style="font-family: Shaker2Lancet-Regular; line-height: 200%; color: #231F20; font-size: 21px;">病毒颗粒)ChAdOx2 RabG的组，并在疫苗接种后第56天进行随访。主要目的是评估安全性。第二个目标是用国际标准化的狂犬病毒中和抗体试验评估免疫原性。在入组后1</span><span style="font-family: Shaker2Lancet-Regular; line-height: 200%; color: #231F20; font-size: 21px;">年的可选随访阶段中，测量抗体维持情况，然后接种已获批准的狂犬病疫苗(以模拟暴露后预防)，并测量回忆反应。该试验已在ClinicalTrials.gov (NCT04162600)上注册，现不接受新的参与者。</span></p><p style="line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><strong style="white-space: normal;"><span style="font-family: Shaker2Lancet-Bold; line-height: 58px; color: #B30437; font-size: 29px;">发现</span></strong></span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">在2020年1月2日至10月28日期间，12名成年人接受了低剂量(3例)、中剂量(3例)和高剂量(6例)ChAdOx2 RabG。参与者报告主要为轻度至中度的反应原性（ reactogenicity）。无严重不良事件发生。在接种56天内，3名中剂量接种者和6名高剂量接种者的病毒中和抗体浓度超过了公认的保护相关性(0.5 IU/mL)(中位数为18·0 IU/mL)。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">低剂量组56天内病毒中和抗体浓度峰值的中位数为0.7 IU/mL(范围0.0 - 54·0 IU/mL)，中剂量组为18·0 IU/mL(0. 7 - 18·0 IU/mL)，高剂量组为18·0 IU/mL(6·0 - 486.0 IU/mL)。9名参与者在1年后返回进行额外的随访。在这9名接受中剂量或高剂量ChAdOx2 RabG的参与者中，有7人的病毒中和抗体滴度超过0.5 IU/mL。在接种第一剂已获批准的狂犬病疫苗的7天内，9名参与者的病毒中和抗体滴度超过0.5 IU/mL。</span></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">本</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">项研究的</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">价值</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:ScalaLancetPro-Bold">在这项研究中，</span>ChAdOx2 RabG显示出可接受的安全性和耐受性，并具有令人鼓舞的免疫原性，支持进一步的临床评估。</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">ChAdOx2 RabG是一种编码狂犬病糖蛋白的新型猴腺病毒载体疫苗，本</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">项</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">研究是首次肌</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">肉</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px"><span style="font-family:Shaker2Lancet-Regular">内单次注射</span>ChAdOx2 RabG的临床试验。该疫苗在这项研究中是安全的，耐受性良好。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">使用国际标准化的狂犬病毒中和抗体试验，</span><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">所有接受中剂量或高剂量</span>ChAdOx2 RabG的参与者在56天内超过了与足够的疫苗接种相关的病毒中和抗体滴度。</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">所有志愿者接种狂犬病疫苗后</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">都</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">检测</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">到了</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">狂犬病糖蛋白特异性细胞免疫反应。</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">所有现有证据的</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">价值</span></strong></p><p style="line-height: 200%">　　　　<strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">虽然灭活狂犬病疫苗非常有效，但</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">也</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">有局限性，包括需要两次或两次以上的就诊</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">而且</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px">费用高。</span></strong><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">部分由于这些原因，在狂犬病负担沉重的国家，人类</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">暴露</span><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">前预防接种的使用率很低。</span></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #FF0000;font-size: 21px">使用现代疫苗平台技术的狂犬病糖蛋白疫苗可能能够克服这些限制，实现低成本的单次</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #FF0000;font-size: 21px">暴露</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #FF0000;font-size: 21px">前预防。</span></strong><strong><span style="font-family: Shaker2Lancet-Regular;line-height: 200%;color: #231F20;font-size: 21px"><span style="font-family:Shaker2Lancet-Regular">这项</span>1期研究为这种方法以及ChAdOx2 RabG候选疫苗的进一步临床研究提供了初步的支持证据</span></strong><span style=";font-family:Shaker2Lancet-Regular;line-height:200%;color:#231F20;font-size:21px">。</span></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 29px">基金</span></strong></p><p style="margin-left: 0;text-indent: 56px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px">由</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px">英国医学研究理事会和工程与自然科学研究理事会</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px">提供</span></strong><strong><span style="font-family: ScalaLancetPro-Bold;line-height: 200%;color: #231F20;font-size: 21px">。</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;font-size: 24px">参考文献</span></strong></p><p style="line-height: 200%;"><em><span style="font-family: Shaker2Lancet-Italic;line-height: 200%;color: #B30437;font-size: 19px">Daniel Jenkin,</span></em><em><span style="font-family: Shaker2Lancet-Italic;line-height: 200%;color: #B30437;font-size: 19px"> et al., </span></em><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px">Safety and immunogenicity of a simian-adenovirus</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px">vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial,</span></strong><span style=";font-family:Calibri;line-height:200%;font-size:19px"> </span><strong><em><span style="font-family: Shaker2Lancet-BoldItalic;line-height: 200%;color: #B30437;font-size: 19px">Lancet Microbe</span></em></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 19px"> 2022</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 19px">,</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #B30437;font-size: 19px"> </span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px">Published online July 27, 2022</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px">，</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px"> </span></strong><a href="https://doi.org/10.1016/S2666-5247(22)00126-4" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #800080;font-size: 19px">https://doi.org/10.1016/S2666-5247(22)00126-4</span></span></strong></a><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 19px">.</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;line-height: 200%;color: #231F20;font-size: 21px"> </span></strong></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1350266.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1350266.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1350072.html" target="_black">Nature：肠道病毒可通过唾液传播</a><br>                    <!--大赛结束-->
                                        
  
</div>
            